- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03230526
Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)
Brain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Parkinson's disease ( MP) is a frequent but heterogeneous neurodegenerative disease in term of clinical presentation(display) and evolutionary profile. The therapeutic coverage(care) of the patients would thus be personalized Such an approach remains still in its infancy in 2017. Better know the factors which determine the evolutionary clinical subcategories is a major question of the current researches on the Parkinson disease. Nigrostriaial inflammation is an interesting candidate. Microglia activation is closely associated with the degenerative process.
Development of the molecular imaging allows to study nigrostriatal inflammation in vivo in human by positron emission tomography (PET) by using the radiotracer of the protein of translocation of 18KDa ( TSPO), considered as a marker of microglia activation Some studies showed an increase of the inflammation in the striatum and in the substantia nigra, the sites of the dopaminergic degeneration (The lesional core of the Parkinson disease is the damage of the dopaminergic nigrostriatale way). However data remain rare and concern small number of patients. Some data are inconsistent because of problems of specificity of the ligands used and variation between populations of studied patients (duration of disease evolution).
In this study, investigators suggest studying by imaging TEP using a ligand new of the TSPO, [18F]DPA-714, microglial brain activation in the early stage of the Parkinson disease and determine wether it is predictive of speed of disease progression.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Nantes, France
- Chu De Nantes
-
Rennes, France
- Centre Eugène Marquis
-
Rennes, France
- CHU de Rennes
-
Tours, France
- CHU de Tours
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients having a Parkinson's disease diagnosed according to the criteria UKPDSBB.
- Diagnosis done less than three years before the date the inclusion.
- Patient Age at diagnosis : between 40 and 65 years.
- Absence of clinical arguments for an associated neurovascular pathology.
- Written consent obtained.
- HAB polymorphism in the genotyping of TSPO gene.
- Brain MRI without following abnormalities: cortical or sub-cortical atrophy or hippocampal atrophy (Scheltens score ≥2), vascular encephalopathy (Fazekas score > 2, > 10 microbleed) or showing signs in favour of atypical parkinson syndrome.
Exclusion Criteria:
- Pregnant woman
- Minor
- Adult protected by the law
- Contraindication to PET-scan
- Contraindication to brain MRI
- History of inflammatory or dysimmune chronic disease
- History of psychiatric disease or drug addiction
- History of cognitive disorders (MMS<26)
- Hypersensibility to iodine derivates or one of these components
- Long-term Treatments which can interfere in neuroinflammation process
- Treatments / substances susceptible to interfere with the 18F-DPA-714
- TSPO gene Polymorphisms rs6971 corresponding to groups of affinity of low affinity (LAB=Low Affinity Binder) or moderated MAB = Mixed Affinity Binder)
- Modification of diagnosis of Parkinson disease during follow-up, in particular towards an atypical parkinson-like syndrome
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Coefficient of correlation between level of microglial striatal activation and the And the dopaminergic denervation kinetics
Time Frame: 24 months
|
Coefficient of correlation between the striatal microglial activation level measured by PET imaging [binding potential (BP) of 18F-DPA-714 in the striatum] and dopaminergic denervation kinetics obtained from two 123I-FP-CIT (DaTscan) scans
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of dopaminergic symptoms (motors)
Time Frame: baseline
|
The equivalent dose of cumulative L-Dopa
|
baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of dopaminergic symptoms (motors)
Time Frame: 18 months
|
The equivalent dose of cumulative L-Dopa
|
18 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of dopaminergic symptoms (motors)
Time Frame: Baseline
|
MDS-UPDRS scale (part III "OFF" - Part III "ON" and part II)
|
Baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of dopaminergic symptoms (motors)
Time Frame: 18 Months
|
MDS-UPDRS scale (part III "OFF" - Part III "ON" and part II)
|
18 Months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of dopaminergic symptoms (motors)
Time Frame: baseline
|
MDS-UPDRS scale (part IV)
|
baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of dopaminergic symptoms (motors)
Time Frame: 18 months
|
MDS-UPDRS scale (part IV)
|
18 months
|
Evaluate the link between the level of striatal microglial activation at inclusion and:the severity of dopaminergic symptoms (non-motors)
Time Frame: baseline
|
QUIP RS
|
baseline
|
Evaluate the link between the level of striatal microglial activation at inclusion and:the severity of dopaminergic symptoms (non-motors)
Time Frame: 18 months
|
QUIP RS
|
18 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (motor)
Time Frame: baseline
|
MDS-UPDRS scale (part III ON : 3.1 ; 3.2 ; 3.9 to 3.13)
|
baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (motor)
Time Frame: 18 months
|
MDS-UPDRS scale (part III ON : 3.1 ; 3.2 ; 3.9 to 3.13)
|
18 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (motor)
Time Frame: baseline
|
MDS-UPDRS scale (part II : 2.13 and part III : 3.11)
|
baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (motor)
Time Frame: 18 months
|
MDS-UPDRS scale (part II : 2.13 and part III : 3.11)
|
18 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: Baseline
|
MDS-UPDRS scale (part I)
|
Baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 18 months
|
MDS-UPDRS scale (part I)
|
18 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: baseline
|
NMS SCALE
|
baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 18 months
|
NMS SCALE
|
18 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: baseline
|
Scopa-Aut Score
|
baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 18 months
|
Scopa-Aut Score
|
18 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: Baseline
|
Evaluation of constipation according to Rome III criteria
|
Baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 18 months
|
Evaluation of constipation according to Rome III criteria
|
18 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: Baseline
|
Detection of hypotension
|
Baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 18 months
|
Detection of hypotension
|
18 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: Baseline
|
Detection of paradoxical sleep disorder, according to the questionnaire for the detection of REM sleep disorders
|
Baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 18 months
|
Detection of paradoxical sleep disorder, according to the questionnaire for the detection of REM sleep disorders
|
18 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: Baseline
|
Epworth's Sleepiness Scale
|
Baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 18 Months
|
Epworth's Sleepiness Scale
|
18 Months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: baseline
|
UPSIT test
|
baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: Baseline
|
MoCA score
|
Baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 18 Months
|
MoCA score
|
18 Months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: Baseline
|
MATTIS scale
|
Baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 18 Months
|
MATTIS scale
|
18 Months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: Baseline
|
Anxiety symptoms assessed using Beck's anxiety inventory
|
Baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 18 months
|
Anxiety symptoms assessed using Beck's anxiety inventory
|
18 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: Baseline
|
Symptoms of depression assessed using the Beck Depression
|
Baseline
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 18 Months
|
Symptoms of depression assessed using the Beck Depression
|
18 Months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of dopaminergic denervation at baseline (DaTscan initial)
Time Frame: Baseline
|
Dopaminergic denervation at inclusion will be measured by the binding potential (BP) of ioflupane (123I-FP-CIT) by regions of interest in the caudate and putamen of the striatum
|
Baseline
|
Assess the relationship between the level of microglial activation in the extra-striatal cortical (cortex and brain stem) regions and the presence of non-motor and axial motor symptoms.
Time Frame: baseline
|
Neurologic Evaluation
|
baseline
|
Assess the relationship between the level of microglial activation in the extra-striatal cortical (cortex and brain stem) regions and the presence of non-motor and axial motor symptoms.
Time Frame: 18 months
|
Neurologic Evaluation
|
18 months
|
Evaluate the link between the level of nigrostriatal microglial activation and the serum level of biological markers of inflammation
Time Frame: Baseline
|
The serum levels of 13 cytokines will be analyzed
|
Baseline
|
Evaluate the link between the level of nigrostriatal microglial activation and the serum level of biological markers of inflammation Evaluate the relationship between the level of nigrostriatal microglial activation
Time Frame: 18 months
|
The serum levels of 13 cytokines will be analyzed
|
18 months
|
Evaluate the relationship between the level of nigrostriatal microglial activation and the serum uric acid level at 0, 18 and 36 months
Time Frame: Baseline
|
Measurement of serum uric acid
|
Baseline
|
Evaluate the relationship between the level of nigrostriatal microglial activation and the serum uric acid level at 0, 18 and 36 months
Time Frame: 18 months
|
Measurement of serum uric acid
|
18 months
|
Analyze the relationship between the level of microglial activation in the black substance at the early stage of MP and the dopaminergic denervation kinetics
Time Frame: 24 months
|
Will be estimated by imaging PET with [18F]DPA-714
|
24 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of dopaminergic symptoms (motors)
Time Frame: 24 months
|
The equivalent dose of cumulative L-Dopa
|
24 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of dopaminergic symptoms (motors)
Time Frame: 24 Months
|
MDS-UPDRS scale (part III "OFF" - Part III "ON" and part II)
|
24 Months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of dopaminergic symptoms (motors)
Time Frame: 24 months
|
MDS-UPDRS scale (part IV)
|
24 months
|
Evaluate the link between the level of striatal microglial activation at inclusion and:the severity of dopaminergic symptoms (non-motors)
Time Frame: 24 months
|
QUIP RS
|
24 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (motor)
Time Frame: 24 months
|
MDS-UPDRS scale (part III ON : 3.1 ; 3.2 ; 3.9 to 3.13)
|
24 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (motor)
Time Frame: 24 months
|
MDS-UPDRS scale (part II : 2.13 and part III : 3.11)
|
24 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 24 months
|
MDS-UPDRS scale (part I)
|
24 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 24 months
|
NMS SCALE
|
24 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 24 months
|
Scopa-Aut Score
|
24 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 24 months
|
Evaluation of constipation according to Rome III criteria
|
24 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 24 months
|
Detection of hypotension
|
24 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 24 months
|
Detection of paradoxical sleep disorder, according to the questionnaire for the detection of REM sleep disorders
|
24 months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 24 Months
|
Epworth's Sleepiness Scale
|
24 Months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 24 Months
|
UPSIT test
|
24 Months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 24 Months
|
MoCA score
|
24 Months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 24 Months
|
MATTIS scale
|
24 Months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 24 Months
|
Anxiety symptoms assessed using Beck's anxiety inventory
|
24 Months
|
Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)
Time Frame: 24 Months
|
Symptoms of depression assessed using the Beck Depression
|
24 Months
|
Evaluate the link between the level of microglial activation in the black substance and outcome 3 to outcome 57
Time Frame: 24 Months
|
MDS-UPDRS scale
|
24 Months
|
Evaluate the link between the level of microglial activation in the black substance and outcome 3 to outcome 57
Time Frame: 24 Months
|
QUIP questionnaire
|
24 Months
|
Evaluate the link between the level of microglial activation in the black substance and outcome 3 to outcome 57
Time Frame: 24 Months
|
NMS questionnaire
|
24 Months
|
Evaluate the link between the level of microglial activation in the black substance and outcome 3 to outcome 57
Time Frame: 24 Months
|
Scopa-Aut Score
|
24 Months
|
Evaluate the link between the level of microglial activation in the black substance and outcome 3 to outcome 57
Time Frame: 24 Months
|
Rome III criteria
|
24 Months
|
Evaluate the link between the level of striatal microglial activation and the level of activation in other brain regions (black substance, bridge and cortex)
Time Frame: 24 months
|
The level of cortical microglial activation measured by fixation of the radioligand 18F-DPA-714, on some volumes of interest in the brain
|
24 months
|
Assess the relationship between the level of microglial activation in the extra-striatal cortical (cortex and brain stem) regions and the presence of non-motor and axial motor symptoms.
Time Frame: 24 months
|
Neurologic Evaluation
|
24 months
|
Evaluate the link between the level of nigrostriatal microglial activation and the serum level of biological markers of inflammation
Time Frame: 24 months
|
The serum levels of 13 cytokines will be analyzed
|
24 months
|
Evaluate the relationship between the level of nigrostriatal microglial activation and the serum uric acid level at 0, 18 and 36 months
Time Frame: 24 months
|
Measurement of serum uric acid
|
24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC17_0012
- 2017-000411-16 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on [18F]DPA-714 PET scan
-
University of Alabama at BirminghamRecruitingBreast CancerUnited States
-
Institut Cancerologie de l'OuestSIRIC ILIADCompletedTriple Negative Breast CancerFrance
-
University Hospital, ToursWithdrawn
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentEnrolling by invitation
-
University Hospital, MontpellierCentre Hospitalier Universitaire de NīmesUnknownKleine-Levin Syndrome | Narcolepsy 1France
-
University of Alabama at BirminghamWithdrawn
-
Ruijin HospitalRecruiting
-
Hospices Civils de LyonNot yet recruitingCAROTID STENOSISFrance
-
University of Alabama at BirminghamActive, not recruitingMyocardial InfarctionUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting